hVIVO secures 6.3 million challenge contract
–News Direct–
hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a 6.3 million contract with a biotechnology client for the testing of their antiviral candidate using the hVIVO Human Rhinovirus Human Challenge Study Model.
The Phase 2a clinical trial is designed as a randomised, double-blinded, placebo-controlled human challenge study and will be conducted at hVIVO's advanced quarantine facilities in Canary Wharf. The primary objective of this study is to assess the impact of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against Human Rhinovirus (HRV) infection in various groups of healthy volunteers.
C...